Zhang Jinghan, Chen Siyue, Sun Xiaoxiao, Chen Sheng, Cheng Qipeng
Anhui Provincial Key Laboratory of Molecular Enzymology and Mechanism of Major Metabolic Diseases, College of Life Sciences, Anhui Normal University, Wuhu 241000, Anhui, China.
Auhui Provincial Engineering Research Centre for Molecular Detection and Diagnostics, College of Life Sciences, Anhui Normal University, Wuhu 241000, Anhui, China.
Curr Pharm Des. 2025;31(13):1007-1019. doi: 10.2174/0113816128343976241117183624.
(KP) is a common and highly pathogenic pathogen, which often causes several serious infections in humans. The rampant and inappropriate use of broad-spectrum antibiotics has fueled a worrisome surge in Multidrug Resistance (MDR) among the strains of , which has significantly boosted the risk and complexity of nosocomial infection transmission in clinical settings. Consequently, this situation presents a substantial challenge to the efficacy of anti-infective treatments, making the development of new and innovative therapeutic approaches important. Bacteriophages (phages) are viruses that can infect and kill bacteria. They and their derived products are now being considered as promising alternatives or adjuncts to antimicrobial therapies for treating bacterial infections in humans, which exhibit a remarkable safety profile and precise host specificity. Numerous studies have also unequivocally demonstrated the remarkable potential of phages in effectively combating MDR infections both and . These studies have explored various approaches to phages, such as phage cocktails, phage-derived enzymes, and the synergistic utilization of phages and antibiotics. Therefore, phage therapy is old but not obsolete, particularly in light of the escalating problem of antimicrobial-resistant infections. Here, we have presented a comprehensive summary of the current knowledge on phage therapy for infections, including phage distribution, characterization of phages, investigations, and cases of clinical study. This review highlights the rapid advancements in phage therapy for , offering a promising avenue for combating this global public health threat.
肺炎克雷伯菌(KP)是一种常见且致病性很强的病原体,常导致人类多种严重感染。广谱抗生素的肆意和不当使用助长了肺炎克雷伯菌菌株中令人担忧的多重耐药性(MDR)激增,这显著增加了临床环境中医院感染传播的风险和复杂性。因此,这种情况对抗感染治疗的疗效构成了重大挑战,使得开发新的创新治疗方法变得至关重要。噬菌体是能够感染并杀死细菌的病毒。它们及其衍生产品现在被认为是治疗人类细菌感染的抗菌疗法的有前景的替代方案或辅助手段,具有显著的安全性和精确的宿主特异性。许多研究也明确证明了噬菌体在有效对抗多重耐药肺炎克雷伯菌感染方面的巨大潜力。这些研究探索了多种应用噬菌体的方法,如噬菌体鸡尾酒疗法、噬菌体衍生酶以及噬菌体与抗生素的协同利用。因此,噬菌体疗法虽旧但未过时,特别是鉴于抗菌药物耐药性肺炎克雷伯菌感染问题日益严重。在此,我们全面总结了目前关于噬菌体疗法治疗肺炎克雷伯菌感染的知识,包括噬菌体分布、噬菌体特征、研究以及临床研究案例。这篇综述强调了噬菌体疗法治疗肺炎克雷伯菌感染的快速进展,为应对这一全球公共卫生威胁提供了一条有前景的途径。